- Strategic alliance drives growth, launching Metoject in Costa Rica, Dominican Republic, Guatemala and Panama, following successful commercialization in Colombia, Chile, and Ecuador.
- This expanded collaboration highlights SteinCares’ strategic role as a bridge between global pharmaceutical companies seeking to enter the Latin American market and the region’s healthcare systems, delivering tailored solutions to address local needs and improve patient outcomes.
San José, Costa Rica, April 2025. SteinCares, a leading specialty healthcare company in Latin America, is expanding its long-standing partnership with Medac GmbH, a global pharmaceutical company based in Germany, to bring Metoject® to four new markets: the Dominican Republic, Panama, Costa Rica, and Guatemala. This expansion builds on Metoject®’s successful introduction in Colombia, Chile, and Ecuador and marks a significant step in improving access to innovative treatments for rheumatic diseases and psoriasis in the region.
This milestone underscores SteinCares’ strategic role as the partner of choice for global pharmaceutical companies looking to enter the Latin American market. Through its one-stop-shop platform—spanning regulatory registration, commercialization, and distribution—SteinCares offers tailored, end-to-end solutions that meet the region’s unique healthcare needs.
“This expansion represents a key milestone in our Metoject® journey and the continued success of our collaboration with Medac,” says Sebastian Katz, Chief Strategy Officer at SteinCares. “We’re proud to bring Metoject® to more patients in Central America, reinforcing our commitment to innovation, access, and affordable healthcare.”
“SteinCares has consistently proven to be a trusted and high-performing partner,” added Jannik Karl Glückstadt, Vice President & Head of Region Americas at Medac GmbH. “This partnership reflects a shared mission: to improve the quality of life for patients living with autoimmune diseases by expanding access to proven, effective therapies.”
Metoject® is an injectable anti-inflammatory and immunosuppressive treatment indicated for rheumatoid arthritis, juvenile idiopathic polyarthritis, Crohn’s disease, psoriasis, and psoriatic arthritis. Its pre-filled syringe format offers improved patient adherence and clinical outcomes, while also reducing costs for healthcare systems.
To ensure the successful introduction of Metoject® in Latin America, SteinCares implemented a comprehensive strategy that included medical education and the generation of local scientific evidence. These initiatives have already demonstrated positive results, with improved patient outcomes in countries like Colombia, Chile and Ecuador.
The expansion of Metoject® to Central America reflects SteinCares’ ongoing commitment to improving access to effective therapies for patients living with chronic conditions. With over 18 million people worldwide affected by rheumatoid arthritis¹, enhancing the availability of proven treatment options like Metoject® plays a vital role in supporting better care across the region.
About SteinCares
SteinCares is a leader in the commercialization and distribution of specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.
For more information, visit http://www.steincares.com/ or follow the company on LinkedIn.
About Medac
Founded in 1970, Medac is dedicated to improving the quality of life for patients worldwide by offering innovative and effective therapeutic solutions. Focused on developing advanced treatments, the company has established itself as a leader in the pharmaceutical sector, providing medications in therapeutic areas such as rheumatology, urology, hematology, and oncology. All its products are manufactured in Germany and other European countries to the highest standards, utilizing its own logistics center and production sites, and are distributed globally. Its diversified portfolio reaches patients in over ninety countries, ensuring quality production and a strong commitment to improving global health.
For more information, visit https://www.medac-group.com/about
